Cargando…

Analysis of CMTM6 and CMTM4 expression as potential regulators of the PD-L1 protein and its association with prognosis in glioma cancer

Detalles Bibliográficos
Autores principales:	Xue, Hui, Qiu, Bin, Wang, Hao, Jiang, Ping, Zhang, Weiwei, Xue, Lixiang, Wang, Junjie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827989/ https://www.ncbi.nlm.nih.gov/pubmed/35983975 http://dx.doi.org/10.3724/abbs.2022108

Ejemplares similares

Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
por: Mezzadra, Riccardo, et al.
Publicado: (2017)

CMTM6 and CMTM4 as two novel regulators of PD-L1 modulate the tumor microenvironment
por: Zhang, Tong, et al.
Publicado: (2022)

Expression Analysis of Canine CMTM6 and CMTM4 as Potential Regulators of the PD-L1 Protein in Canine Cancers
por: Takeuchi, Hiroto, et al.
Publicado: (2020)

CMTM6 and CMTM7: New leads for PD‐L1 regulation in breast cancer cells undergoing EMT
por: Xiao, Malina, et al.
Publicado: (2022)

Epithelial to Mesenchymal Transition Regulates Surface PD-L1 via CMTM6 and CMTM7 Induction in Breast Cancer
por: Xiao, Malina, et al.
Publicado: (2021)

Coexpression of CMTM6 and PD-L1 as a predictor of poor prognosis in macrotrabecular-massive hepatocellular carcinoma
por: Liu, Li-Li, et al.
Publicado: (2020)

CMTM6 significantly relates to PD-L1 and predicts the prognosis of gastric cancer patients
por: Li, Xin, et al.
Publicado: (2020)

The association of CMTM6 expression with prognosis and PD-L1 expression in triple-negative breast cancer
por: Tian, Yiping, et al.
Publicado: (2021)

CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas
por: Guan, Xiudong, et al.
Publicado: (2018)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

CMTM6, the newly identified PD-L1 regulator, correlates with PD-L1 expression in lung cancers
por: Gao, Feng, et al.
Publicado: (2019)

Expression and Clinical Significance of CMTM6 and PD-L1 in Triple-Negative Breast Cancer
por: Shi, Shuai, et al.
Publicado: (2022)

CMTM6 knockdown prevents glioma progression by inactivating the mTOR pathway
por: Wei, Li, et al.
Publicado: (2022)

Co-expression of CMTM6 and PD-L1: a novel prognostic indicator of gastric cancer
por: Zhang, Chao, et al.
Publicado: (2021)

New prognostic biomarker CMTM3 in low grade glioma and its immune infiltration
por: Li, Shoubin, et al.
Publicado: (2022)

Overexpressed CMTM6 Improves Prognosis and Associated With Immune Infiltrates of Ovarian Cancer
por: Yin, Bo, et al.
Publicado: (2022)

CMTM6 expression in M2 macrophages is a potential predictor of PD-1/PD-L1 inhibitor response in colorectal cancer
por: Wu, Xuehui, et al.
Publicado: (2021)

CMTM Family and Gastrointestinal Tract Cancers: A Comprehensive Review
por: Li, Jie, et al.
Publicado: (2022)

CMTM8 inhibits the carcinogenesis and progression of bladder cancer
por: GAO, DENGHUI, et al.
Publicado: (2015)

HuR up-regulates cell surface PD-L1 via stabilizing CMTM6 transcript in cancer
por: Liu, Yanbin, et al.
Publicado: (2021)

CMTM6-Deficient Monocytes in ANCA-Associated Vasculitis Fail to Present the Immune Checkpoint PD-L1
por: Zeisbrich, Markus, et al.
Publicado: (2021)

CMTM6 Stabilizes PD‐L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma
por: Yugawa, Kyohei, et al.
Publicado: (2020)

CMTM3 inhibits cell migration and invasion and correlates with favorable prognosis in gastric cancer
por: Su, Yu, et al.
Publicado: (2014)

Prognostic Implications of Pan-Cancer CMTM6 Expression and Its Relationship with the Immune Microenvironment
por: Zhao, Yanbin, et al.
Publicado: (2021)

Clinical significance of CMTM4 expression in hepatocellular carcinoma
por: Bei, Chunhua, et al.
Publicado: (2017)

Expression and clinical significance of CMTM1 in hepatocellular carcinoma
por: Song, Xin, et al.
Publicado: (2021)

Suppression of Tumor or Host Intrinsic CMTM6 Drives Antitumor Cytotoxicity in a PD-L1–Independent Manner
por: Long, Yiru, et al.
Publicado: (2023)

CMTM6 overexpression confers trastuzumab resistance in HER2-positive breast cancer
por: Xing, Fei, et al.
Publicado: (2023)

Schwann-cell-derived CMTM6 restricts radial axonal growth
por: Elazar, Nimrod, et al.
Publicado: (2020)

CMTM3 as a Potential New Immune Checkpoint Regulator
por: Shen, Qian, et al.
Publicado: (2022)

CMTM7 inhibits breast cancer progression by regulating Wnt/β-catenin signaling
por: Chen, Zhao-Hui, et al.
Publicado: (2023)

Expression of CMTM4 shows clinical significance in lung cancer
por: Zhu, Xiaonian, et al.
Publicado: (2020)

CMTM6 expression as a potential biomarker for immunotherapy in metastatic renal cell carcinoma
por: Tulchiner, Gennadi, et al.
Publicado: (2021)

CMTM6 is highly expressed in lung adenocarcinoma and can be used as a biomarker of a poor diagnosis
por: Jia, Daqi, et al.
Publicado: (2023)

High membrane expression of CMTM6 in hepatocellular carcinoma is associated with tumor recurrence
por: Muranushi, Ryo, et al.
Publicado: (2021)

Loss of CMTM6 promotes DNA damage-induced cellular senescence and antitumor immunity
por: Wang, Hanfeng, et al.
Publicado: (2022)

Circular RNA hsa_circ_0067842 facilitates tumor metastasis and immune escape in breast cancer through HuR/CMTM6/PD-L1 axis
por: Li, Juan, et al.
Publicado: (2023)

CMTM6 as a candidate risk gene for cervical cancer: Comprehensive bioinformatics study
por: Huang, Xiaoting, et al.
Publicado: (2022)

Prognostic significance and immune characteristics of CMTM4 in hepatocellular carcinoma
por: Tan, Shengkui, et al.
Publicado: (2022)

Current Opinions on the Relationship Between CMTM Family and Hepatocellular Carcinoma
por: Pei, Yulin, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1q9uoab2kjsu0prk4r1bv20go8